Afala tablets, no. 100

Afala is indicated for use in adults.

• benign prostatic hyperplasia of I and II stages;

• chronic abacterial prostatitis (as an anti-inflammatory and analgesic agent);

• dysuric disorders (frequent urge to urinate, including at night, difficulty urinating, pain or discomfort in the perineal region) accompanying benign prostatic hyperplasia of stages I and II and chronic abacterial prostatitis.

Inside, not during meals. 2 tables. at the reception (keep the pill in your mouth until it is completely dissolved). The drug should be taken twice a day, morning and evening (after and before bedtime). The recommended duration of taking the drug is 16 weeks.

With severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, the drug is indicated up to 4 times a day.

If necessary, on the recommendation of a doctor, it is possible to repeat the course of treatment in 1Ц4 months.

Lozenges

1 tablet contains active substances: antibodies to PSA affinity purified * 0.003 g

excipients: lactose monohydrate (lactose) - 0.267 g; MCC - 0.03 g; magnesium stearate - 0.003 g * applied to lactose in the form of a water-alcohol mixture with a content of not more than 10-15 ng / g of the active form of the active substance

• Age up to 18 years due to insufficient data on efficacy and safety for this age;

• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

• increased individual sensitivity to the components of the drug.

pharmachologic effect

Reduces the phenomenon of inflammation and edema in the prostate gland, normalizes its functional state. Improves urodynamics, reduces the volume of residual urine, normalizes the tone of the lower urinary tract, helps to reduce dysuric disorders.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of ultra-low doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of Afala.

Side effect

Possible reactions of increased individual sensitivity to the components of the drug.

Application during pregnancy and lactation

Afala is not intended for use in women.

Application in children

Use under the age of 18 is contraindicated due to insufficient data on efficacy and safety.

special instructions

The drug contains lactose monohydrate, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or congenital lactase deficiency.

Influence on the ability to drive vehicles and mechanisms

Afala does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Overdose

In case of an accidental overdose, dyspeptic phenomena are possible due to the fillers included in the dosage form.

Drug interactions

No cases of incompatibility with other drugs have been registered to date.